Managed entry agreements
2014
Background New scientific progress in the “precision medicines” direction and a better diagnosis of rare diseases have led Regulators and Payers to focus their vigilance towards the real life setting. Although Regulators and Payers are taking into consideration patient pressures for rapid access to treatment, nevertheless they must balance the difficulties of taking significant decision coping with uncertainties when deciding on pricing and reimbursement processes.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
11
Citations
NaN
KQI